专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2015142583A1 NEW GADOLINIUM-BASED CONTRAST AGENTS FOR SENSITIVE DETECTION OF ZN2+ WITH MRI 审中-公开
标题翻译：新型基于GADOLINIUM的对比剂用于敏感检测ZN2 +与MRI
公开(公告)号：WO2015142583A1
公开(公告)日：2015-09-24
申请号：PCT/US2015/019928
申请日：2015-03-11
申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
发明人： PREIHS, Christian , YU, Jing , JORDAN, Veronica Clavijo , WU, Yunkou , NASR, Khaled , SHERRY, A. Dean
IPC分类号： A61K49/06 , A61K51/04
CPC分类号： A61K49/108 , A61B5/055 , A61K49/106 , C07D213/38
摘要： In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.
摘要翻译：在一些方面，本公开提供了新的配体，其可用于制备用于检测锌的新型MRI造影剂。在另外的方面，本公开还提供了用作成像剂及其组合物的方法。

22. 发明申请

WO2015117911A1 PROCESS FOR PURIFYING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID 审中-公开
标题翻译：纯化1,4,7,10-四氮杂环十二烷-1,4,7,10-四氢酸的方法
公开(公告)号：WO2015117911A1
公开(公告)日：2015-08-13
申请号：PCT/EP2015/052033
申请日：2015-02-02
申请人： AGFA HEALTHCARE
发明人： BUFFEL, Diederik , BOI, Xavier , PYPE, Judith
IPC分类号： C07D257/02
CPC分类号： A61K49/108 , A61K47/18 , B01D61/027 , B01D2311/2649 , B01D2311/2673 , B01D2315/16 , C07D257/02 , C07D295/15 , C07F5/003
摘要： A process for purifying a compound of formula (1), comprising the following steps: a) adding an acid to an aqueous solution of the compound of formula 1, including salts thereof so as to obtain a pH ≤ 3 whereby a slurry is obtained; and b) filtering the slurry and at least one time washing the obtained precipitate with a liquid comprising water; and c) dissolving the precipitate obtained in step b) in water to obtain an aqueous solution; and d) filtering of the solution obtained in step c) over a nanofiltration membrane having a Molecular Weight Cut Off in the range from 150 to 500 and wherein optionally, between step c) and step d) the pH of the aqueous solution is adjusted to a pH value in the pH range as specified by the manufacturer of the nanofiltration membrane. A process for preparing a gadolinium complex of the purified compound of formula 1 is also disclosed. This gadolinium complex can be used for making a pharmaceutical composition as a contrast agent for magnetic resonance imaging.
摘要翻译：一种纯化式（1）化合物的方法，包括以下步骤：a）向式1化合物的水溶液中加入酸，包括其盐，以获得pH≤3，由此得到浆料; 和b）过滤浆料，并至少一次用包含水的液体洗涤所获得的沉淀物; 和c）将步骤b）中获得的沉淀溶解在水中以获得水溶液; 以及d）将步骤c）中获得的溶液过滤到分子量截留在150-500范围内的纳滤膜中，并且其中任选地在步骤c）和步骤d）之间，将水溶液的pH调节至在纳米过滤膜制造商规定的pH范围内的pH值。还公开了制备纯化的式1化合物的钆络合物的方法。该钆络合物可用于制备用作磁共振成像的造影剂的药物组合物。

23. 发明申请

WO2014161925A1 PROCESS FOR PRODUCING A COMPLEX OF A LANTHANIDE WITH A MACROCYCLIC LIGAND 审中-公开
标题翻译：用于制造具有大环配体的兰沙坦复合物的方法
公开(公告)号：WO2014161925A1
公开(公告)日：2014-10-09
申请号：PCT/EP2014/056670
申请日：2014-04-03
申请人： AGFA HEALTHCARE
发明人： BUFFEL, Diederik , LEBLANS, Paul , VENNEMAN, Jan
IPC分类号： A61K49/18 , A61K49/10
CPC分类号： A61K49/108 , A61K49/18
摘要： A process for producing a complex of a lanthanide or similar compound with a macrocyclic ligand, wherein the ratio of macrocyclic ligand in free form in relation to the lanthanide or similar compound is equal or more than 0.002% mol/mol, comprising the following steps: a) measuring the moisture content in a sample of the macrocyclic ligand; and b) mixing an amount G of the lanthanide with an amount X3 of the macrocyclic ligand with the proviso that X3= LG+Lf + M, wherein LG is the amount of macrocyclic ligand necessary for complexing the amount G of lanthanide or similar compound; Lf is an excess amount of the macrocyclic ligand; and M is the amount of moisture present in the amount X3 of the macrocyclic ligand.
摘要翻译：制备镧系元素或类似化合物与大环配体的配合物的方法，其中游离形式的与镧系元素或类似化合物相关的大环配体的比例等于或大于0.002％mol / mol，包括以下步骤： a）测量大环配体样品中的水分含量; 和b）将镧系元素的量G与大环配体的量X3混合，条件是X3 = LG + Lf + M，其中LG是络合镧系元素或类似化合物的量G所需的大环配体的量; Lf是过量的大环配体; M是大环配体的量X3中存在的水分量。

24. 发明申请

WO0182795A3 MAGNETIC RESONANCE IMAGING AGENTS FOR THE DELIVERY OF THERAPEUTIC AGENTS 审中-公开
标题翻译：用于输送治疗药物的磁共振成像剂
公开(公告)号：WO0182795A3
公开(公告)日：2002-05-02
申请号：PCT/US0114665
申请日：2001-05-04
申请人： RES CORP TECHNOLOGIES INC , MEADE THOMAS J
发明人： MEADE THOMAS J
IPC分类号： A61K49/08
CPC分类号： A61K49/108 , A61K49/103 , A61K49/105 , A61K49/106
摘要： The invention relates to novel magnetic resonance imaging contrast agents that report on physiological events in a conditional fashion and simultaneously detect the delivery and/or activation of a therapeutically active agent.
摘要翻译：本发明涉及以条件方式报告生理事件并同时检测治疗活性剂的递送和/或活化的新型磁共振成像造影剂。

25. 发明申请

WO01082795A2 MAGNETIC RESONANCE IMAGING AGENTS FOR THE DELIVERY OF THERAPEUTIC AGENTS 审中-公开
标题翻译：用于输送治疗药物的磁共振成像剂
公开(公告)号：WO01082795A2
公开(公告)日：2001-11-08
申请号：PCT/US2001/014665
申请日：2001-05-04
IPC分类号： A61K49/08 , A61B5/00
CPC分类号： A61K49/108 , A61K49/103 , A61K49/105 , A61K49/106
摘要： The invention relates to novel magnetic resonance imaging contrast agents that report on physiological events in a conditional fashion and simultaneously detect the delivery and/or activation of a therapeutically active agent.
摘要翻译：本发明涉及以条件方式报告生理事件并同时检测治疗活性剂的递送和/或活化的新型磁共振成像造影剂。

26. 发明申请

WO2017136700A1 NON-NUTRITIVE SWEETENERS AND POLYOLS AS IMAGING AGENTS 审中-公开
标题翻译：非营养型甜味剂和多元醇作为成像剂
公开(公告)号：WO2017136700A1
公开(公告)日：2017-08-10
申请号：PCT/US2017/016473
申请日：2017-02-03
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , SIDRA MEDICAL AND RESEARCH CENTER
发明人： MARINCOLA, Francesco, M. , REDDY, Ravinder , HARIS, Mohammad , HARIHARAN, Hari , BAGGA, Puneet , SCHNALL, Mitchell, D.
IPC分类号： A23L27/30 , A61B5/055 , A61B6/03 , A61K49/06 , A61K49/10
CPC分类号： A61K51/0421 , A61B5/055 , A61B6/037 , A61K49/108 , A61K51/0491
摘要： The present disclosure relates to magnetic resonance imaging (MRI) methods comprising (i) obtaining a baseline chemical exchange saturation transfer (CEST) MRI image of a patient, (ii) administering an effective amount of a non-nutritive sweetener to the patient, and (iii) obtaining one or more test CEST MRI image of the patient subsequent to the administering step (ii); wherein the step (i) and (iii) acquisition parameters are substantially the same. The non- nutritive sweetener may include a natural or artificial sugar alcohol, polyol, or combinations or derivatives thereof.
摘要翻译：本公开涉及磁共振成像（MRI）方法，其包括（i）获得患者的基线化学交换饱和转移（CEST）MRI图像，（ii）施用有效量的非（iii）在所述施用步骤（ii）之后获得所述患者的一个或多个测试CEST MRI图像;以及（iii）在所述施用步骤（ii）之后获得所述患者的一个或多个测试CEST MRI图像。其中步骤（i）和（iii）采集参数基本相同。非营养甜味剂可以包括天然或人造糖醇，多元醇或其组合或衍生物。

27. 发明申请

WO2017046694A1 PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF GADOTERATE MEGLUMINE 审中-公开
标题翻译：制备甘油三酯的药物制剂的方法
公开(公告)号：WO2017046694A1
公开(公告)日：2017-03-23
申请号：PCT/IB2016/055436
申请日：2016-09-13
申请人： LEIUTIS PHARMACEUTICALS PVT LTD
发明人： KOCHERLAKOTA, Chandrashekhar , BANDA, Nagaraju
IPC分类号： A61K49/06
CPC分类号： A61K49/108 , A61K49/18
摘要： The present invention relates to a process for preparing a liquid parenteral formulation of Gadoterate meglumine which is used as a contrast agent for magnetic resonance imaging.
摘要翻译：本发明涉及用作磁共振成像造影剂的加藤酸葡甲胺的液体肠胃外制剂的制备方法。

28. 发明申请

WO2017021686A1 NEURODEGENERATIVE DISORDERS 审中-公开
标题翻译：神经损伤性疾病
公开(公告)号：WO2017021686A1
公开(公告)日：2017-02-09
申请号：PCT/GB2016/052206
申请日：2016-07-21
申请人： KRAN LIFE SCIENCES LLP
发明人： NITHIYANANDAM, Krtin
IPC分类号： A61K49/04 , A61K49/16 , A61K49/18 , B82Y5/00 , A61K47/69 , A61P25/28
CPC分类号： A61K49/0002 , A61K47/6879 , A61K47/6923 , A61K47/6929 , A61K49/0428 , A61K49/108 , A61K49/1824 , A61K49/1881 , B82Y5/00 , G01N33/6896 , G01N2333/4709
摘要： An amyloidogenic peptide biospecific agent comprises a nanoparticle which is visible under near infrared (NIR) and/or using Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT). The biospecific agent further comprises at least one antibody or antigen binding fragment thereof, which is immunospecific for a transferrin receptor and an amyloidogenic peptide.
摘要翻译：淀粉样蛋白衍生肽生物特异性试剂包括在近红外（NIR）和/或使用磁共振成像（MRI）和/或计算机断层扫描（CT）下可见的纳米颗粒。生物特异性试剂还包含至少一种抗体或其抗原结合片段，其对于转铁蛋白受体和淀粉样变性肽是免疫特异性的。

29. 发明申请

WO2016090491A1 TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP 审中-公开
标题翻译：含有氢化官能团的目标对比剂
公开(公告)号：WO2016090491A1
公开(公告)日：2016-06-16
申请号：PCT/CA2015/051304
申请日：2015-12-10
申请人： RF THERAPEUTICS INC.
发明人： ZHANG, Jidong , CURRY, Ken
IPC分类号： A61K49/00 , A61K31/198 , A61K31/395 , A61K31/404 , A61K31/4192 , A61K49/04 , A61K49/10 , A61K51/04 , C07C243/38 , C07D209/42 , C07D249/04
CPC分类号： A61K49/101 , A61K49/085 , A61K49/10 , A61K49/108 , C07C243/38 , C07D209/42 , C07D249/04 , C07D257/02 , C07D403/12 , C07D403/14
摘要： Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes a hydrazide functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal- complexable portion of the contrast agent. The portion that is not bound to a metal ion localizes the contrast agent to necrotic tissue in the subject.
摘要翻译：本文描述了用于给予受试者的造影剂。造影剂包括包含酰肼官能团的靶向部分; 与金属络合部分结合的金属离子; 以及将造影剂的靶向部分和金属可络合部分连接的接头。不结合金属离子的部分将造影剂定位于受试者的坏死组织。

30. 发明申请

WO2016083605A1 LANTHANIDE COMPLEX FORMULATIONS 审中-公开
标题翻译：兰萨坦复合制剂
公开(公告)号：WO2016083605A1
公开(公告)日：2016-06-02
申请号：PCT/EP2015/077970
申请日：2015-11-27
申请人： GE HEALTHCARE AS
发明人： MEIJER, Andreas, Richard , THANING, Mikkel, Jacob
IPC分类号： C07D257/00
CPC分类号： A61K49/108 , A61K9/0019 , A61K31/28 , A61K49/106 , C07D257/00
摘要： The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.
摘要翻译：本发明涉及从大环螯合剂的镧系元素金属络合物中除去金属离子杂质如钙的方法。该方法使用清除树脂来除去金属离子，从螯合剂中移出，过量的镧系元素离子。还提供了通过加入限定的过量螯合剂从纯化的镧系金属络合物制备MRI造影剂的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式